Medtronic PLC $MDT Shares Sold by Maia Wealth LLC

Maia Wealth LLC trimmed its position in Medtronic PLC (NYSE:MDT) by 17.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,888 shares of the medical technology company’s stock after selling 595 shares during the period. Maia Wealth LLC’s holdings in Medtronic were worth $252,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in MDT. Gilbert & Cook Inc. grew its holdings in shares of Medtronic by 1.9% in the 2nd quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock worth $532,000 after acquiring an additional 114 shares during the last quarter. Red Spruce Capital LLC increased its holdings in shares of Medtronic by 0.5% in the 2nd quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock valued at $2,067,000 after purchasing an additional 118 shares during the period. Certior Financial Group LLC increased its stake in Medtronic by 3.7% in the 1st quarter. Certior Financial Group LLC now owns 3,450 shares of the medical technology company’s stock valued at $310,000 after buying an additional 122 shares during the period. PrairieView Partners LLC increased its stake in shares of Medtronic by 3.6% in the second quarter. PrairieView Partners LLC now owns 3,726 shares of the medical technology company’s stock worth $324,000 after acquiring an additional 128 shares during the last quarter. Finally, Baker Avenue Asset Management LP raised its stake in shares of Medtronic by 3.1% during the 1st quarter. Baker Avenue Asset Management LP now owns 4,558 shares of the medical technology company’s stock worth $410,000 after purchasing an additional 136 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.26% of the company’s stock.

Wall Street Analyst Weigh In

MDT has been the topic of several recent research reports. Argus raised their target price on Medtronic from $105.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, August 26th. Cowen reiterated a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. Sanford C. Bernstein set a $111.00 price target on Medtronic in a report on Wednesday, November 19th. Daiwa Capital Markets increased their price objective on shares of Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Finally, Royal Bank Of Canada raised their target price on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $109.72.

Medtronic Stock Down 0.2%

NYSE:MDT opened at $105.13 on Thursday. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $106.33. The firm has a market capitalization of $134.85 billion, a P/E ratio of 28.96, a P/E/G ratio of 2.42 and a beta of 0.77. The stock’s fifty day simple moving average is $95.68 and its 200-day simple moving average is $91.39.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The company had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the previous year, the business earned $1.26 EPS. The firm’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.